Cabaletta Bio, Inc. 8-K

What Happened

• On June 3, 2026 Cabaletta Bio announced new clinical and translational data for rese‑cel across autoimmune indications (presented at EULAR 2026) and furnished a press release and updated corporate presentation. Data cover 52 evaluable patients treated with rese‑cel: 17 myositis, 20 lupus, and 15 systemic sclerosis (SSc). The company highlighted encouraging early results with preconditioning‑free (PC‑free) rese‑cel in lupus and reported consistent translational profiles with and without preconditioning. Cabaletta also outlined planned registrational and development milestones, including a planned SSc registrational study to start in 4Q26 and topline data for the DM/ASyS registrational cohort expected mid‑2027.

Key Details

• Patient totals and safety: 52 evaluable autoimmune patients (17 myositis, 20 lupus, 15 SSc); most patients experienced no CRS or only transient fever and the majority had no ICANS across cohorts (examples: 17/17 no or Grade 1 CRS in myositis; 14/15 no ICANS in SSc cohort).
• Myositis (RESET‑Myositis): 80% (8/10) of DM/ASyS Phase 1/2 cohort would have met the registrational cohort primary endpoint; DM: 83% (5/6) IM‑free moderate‑to‑major TIS at 16 weeks, durable to as long as 1.5 years.
• SSc (RESET‑SSc): Patients with ILD showed median +7.5% ppFVC improvement at 36 weeks (IM‑free); rCRISS‑25 achieved in 83% (5/6) and rCRISS‑50 in 67% (4/6) at 36 weeks off IMs.
• SLE (RESET‑SLE): In two PC‑free lupus patients, one achieved deep B‑cell depletion and the other ~90% peripheral B‑cell reduction; preconditioning cohorts showed 75% (6/8) achieved DORIS at 12 months while off IMs, and 83% (15/18) remain IM‑free on no/low‑dose steroids.

Why It Matters

• These results indicate rese‑cel may produce meaningful clinical responses across multiple autoimmune diseases while enabling many patients to discontinue other immunomodulators and use low/no steroids—important endpoints for patient quality of life and regulatory evaluation.
• Early PC‑free activity in lupus (and prior pemphigus results) suggests potential for a lower‑burden dosing approach that could expand patient access if confirmed, but Cabaletta’s statements are forward‑looking and subject to clinical, regulatory and safety risks outlined in the filing.
• Near‑term milestones investors should watch: planned SSc registrational study start in 4Q26, DM/ASyS registrational topline data mid‑2027, and planned inclusion of juvenile DM (JDM) in a 2H27 BLA strategy.